Unlocking the potential: FKK6 as a microbial mimicry-based therapy for chronic inflammation-associated colorectal cancer in a murine model
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
40023602
DOI
10.1016/j.jpet.2024.100059
PII: S0022-3565(24)38708-7
Knihovny.cz E-zdroje
- Klíčová slova
- Colon cancer, Inflammation, Microbial metabolites, Pregnane X receptor,
- MeSH
- azoxymethan toxicita MeSH
- chronická nemoc MeSH
- indoly farmakologie terapeutické užití MeSH
- kolitida farmakoterapie chemicky indukované metabolismus patologie MeSH
- kolorektální nádory * farmakoterapie metabolismus patologie MeSH
- modely nemocí na zvířatech * MeSH
- molekulární mimikry MeSH
- myši inbrední C57BL * MeSH
- myši MeSH
- nádory asociované s kolitidou patologie farmakoterapie metabolismus MeSH
- síran dextranu toxicita MeSH
- zánět farmakoterapie metabolismus MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- azoxymethan MeSH
- indoly MeSH
- síran dextranu MeSH
Chronic intestinal inflammation significantly contributes to the development of colorectal cancer and remains a pertinent clinical challenge, necessitating novel therapeutic approaches. Indole-based microbial metabolite mimics Felix Kopp Kortagere 6 (FKK6), which is a ligand and agonist of the pregnane X receptor (PXR), was recently demonstrated to have PXR-dependent anti-inflammatory and protective effects in a mouse model of dextran sodium sulfate (DSS)-induced acute colitis. Here, we examined the therapeutic potential of FKK6 in a mouse model (C57BL/6 FVB humanized PXR mice) of colitis-associated colon cancer (CAC) induced by azoxymethane and DSS. FKK6 (2 mg/kg) displayed substantial antitumor activity, as revealed by reduced size and number of colon tumors, improved colon histopathology, and decreased expression of tumor markers (c-MYC, β-catenin, Ki-67, and cyclin D) in the colon. In addition, we carried out a chronic toxicity (30 days) assessment of FKK6 (1 mg/kg and 2 mg/kg) in C57BL/6 mice. Histological examination of tissues, biochemical blood analyses, and immunohistochemical staining for Ki-67 and γ-H2AX showed no difference between FKK6-treated and control mice. Comparative metabolomic analyses in mice exposed for 5 days to DSS and administered with FKK6 (0.4 mg/kg) revealed no significant effects on several classes of metabolites in the mouse fecal metabolome. Ames and micronucleus tests showed no genotoxic and mutagenic potential of FKK6 in vitro. In conclusion, anticancer effects of FKK6 in azoxymethane/DSS-induced CAC, together with FKK6 safety data from in vitro tests and in vivo chronic toxicity study, and comparative metabolomic study, are supportive of the potential therapeutic use of FKK6 in the treatment of CAC. SIGNIFICANCE STATEMENT: Microbial metabolite mimicry proposes that chemical mimics of microbial metabolites that serve to protect hosts against aberrant inflammation in the gut could serve as a new paradigm for the development of drugs targeting inflammatory bowel disease if, like the parent metabolite, is devoid of toxicity but more potent against the microbial metabolite receptor. We identified a chemical mimic of Felix Kopp Kortagere 6, and we propose that Felix Kopp Kortagere 6 is devoid of toxicity yet significantly reduces tumor formation in an azoxymethane-dextran sodium sulfate model of murine colitis-induced colon cancer.
Analytical Imaging Facility Albert Einstein College of Medicine Bronx New York
Arizona Metabolomics Laboratory College of Health Solutions Arizona State University Phoenix Arizona
Department of Cell Biology and Genetics Faculty of Science Palacký University Olomouc Czech Republic
Department of Medicine and Genetics Albert Einstein College of Medicine Bronx New York
Department of Pathology Albert Einstein College of Medicine Bronx New York
Citace poskytuje Crossref.org